List view / Grid view
20 December 2022 | By Eurofins DiscoverX Corp.
In this webinar, we present an approach for building MOA-based, simple, ready-to-use GLP-1 and GLP-2 bioassays and discuss assay validation results from Eurofins BPT.
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
9 June 2022 | By Eurofins DiscoverX
Watch this on-demand virtual roundtable to explore how the simple, thaw-and-use bioassay format improves assay workflow and helps attain high assay reproducibility.
A collaboration between Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) has been established to source cellular functional assays from the global academic community, with the goal of developing novel screens and identifying targets and therapeutic candidates for unmet medical needs. Here, Dr Denise Barrault, Director of…
A new study from Niigata University has found a binding protein that is vital for proper development of the central nervous system.
A novel antiviral drug called thapsigargin (TG) blocked COVID-19 infection in cells, including all new variants, in a pre-clinical study.
A new study links tumour necrosis factor seen in rheumatoid arthritis with T cell dysfunction, potentially leading to new therapies.
Scientists reveal that higher levels of inflammatory chemicals involved in fat metabolism occur in people with amyotrophic lateral sclerosis.
Ncardia has formed a strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services.
The study paves the way for the construction of complex nanoscale computers for the prevention and treatment of cancer and other diseases.
Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
19 August 2021 | By Eurofins Discovery
Watch this on-demand webinar that discusses the two assays developed by Eurofins and why they represent a more physiologic and dynamic system to provide a more comprehensive pre-clinical model for cardiac liability assessment.
Researchers have developed a new method that manipulates tiny water droplets in lab-on-chip applications for cell culturing and drug screening.
In this article, Dr Jon Volmer and Dr Jon Lenn discuss a new approach to formulation models to test drug delivery based on reconstituted nasal epithelium.
Researchers identified a potential therapeutic involving the inhibition of PIP4K enzymes which could enable the immune system to destroy tumour cells.
